Real-time regulatory updates from DEA, DOJ, FDA, CMS, and all 50 state medical boards — curated and analyzed by AI, reviewed by compliance experts. Built to help you stay ahead of healthcare regulation changes.
All 50 States + DC
350+ Regulatory Topics
Regulatory Intelligence Feed
0 articles published
Guides & Templates
In-Depth Compliance Resources
Comprehensive guides, checklists, and templates to help you navigate healthcare compliance — from CPOM structuring to GFE requirements and medical director agreements.
Our AI-powered intelligence engine monitors DEA, DOJ, FDA, CMS, and all 50 state medical boards so you never miss a compliance update that affects your business.
The U.S. Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) have announced a fourth temporary extension of telemedicine flexibilities for prescribing controlled medications. This action allows practitioners to continue prescribing controlled substances via telehealth without a prior in-person visit until December 31, 2026, preventing disruptions in patient care while permanent regulations are finalized.
The U.S. Department of Health and Human Services (HHS), through its Health Resources and Services Administration (HRSA), has announced a revised 340B Rebate Model Pilot Program. This Pilot will implement a rebate mechanism for certain drugs, allowing qualifying manufacturers to effectuate the 340B ceiling price via rebates instead of upfront discounts. This initiative follows stakeholder input and aims to build on established rebate programs for a limited set of drugs.
The Food and Drug Administration (FDA) has issued a final order permanently debarring Angela Anatilde Baquero from providing services in any capacity to persons with approved or pending drug product applications. This action stems from Ms. Baquero's conviction for a felony under Federal law related to the development or approval of a drug product. The debarment order became applicable on August 3, 2026, after Ms. Baquero waived her right to a hearing.
The Food and Drug Administration (FDA) has issued a final order permanently debarring Ricardo Andres Acuna from providing services to any entity with an approved or pending drug product application. This action stems from a finding that Mr. Acuna was convicted of a federal felony related to drug product development or approval processes. Mr. Acuna failed to request a hearing, thereby waiving his right to contest the debarment.
The Federal Trade Commission (FTC) has finalized an enforcement action against telehealth provider NextMed, its principals, for deceptive weight-loss advertising practices related to GLP-1 programs, unsubstantiated claims, the use of fake reviews, and unfair billing and cancellation procedures. This action resulted in a $150,000 payment for consumer refunds and specific prohibitions to ensure fair advertising and transparent billing practices. This follows another recent FTC action against Hims & Hers for privacy and billing concerns.
The Kentucky Board of Dentistry outlines comprehensive requirements for dentists prescribing controlled substances, including mandatory DEA registration, an active KASPER account, and adherence to electronic prescribing (EPCS) rules. Dentists must operate within their defined scope of practice for oral, maxillofacial, and associated structures, emphasizing compliance with both state and federal regulations to combat opioid abuse.
Dr. David Antonio Becerril was sentenced to 40 months imprisonment and ordered to pay $1.25 million in restitution for his role in a nationwide telemarketing conspiracy that defrauded Medicare through fraudulent telemedicine practices. His conviction in September 2025 involved 16 felony counts, including healthcare and wire fraud.
The Department of Justice's recent National Health Care Fraud Takedown charged 455 defendants, highlighting $1.2 billion in alleged telemedicine fraud and demonstrating a continued federal focus on the telehealth sector. This action is underscored by a recent conviction of a medical supply company owner and chiropractor in Florida for a $30 million scheme involving fraudulent orders for unneeded medical equipment through purchasing patient data and practitioner signatures.
The Food and Drug Administration (FDA) has issued a final order debarring Francis Esteban Matos for a period of 5 years from importing or offering for import any drug into the United States. This action is based on a felony conviction under Federal law related to the importation of a drug or controlled substance. Mr. Matos waived his right to a hearing by failing to respond to the proposed debarment notice.
California has transitioned to active Attorney General enforcement of Corporate Practice of Medicine (CPOM) restrictions, focusing specifically on contractual arrangements that grant Management Services Organizations (MSOs) or investors de facto control over medical practices. A recent $2.3 million settlement with a dental services organization highlights the state's heightened scrutiny on MSO influence over clinical decisions, practice ownership, and public communications.
Kentucky's Medical Cannabis Program outlines specific requirements for physicians and advanced practice registered nurses (APRNs) to provide written certifications for medical cannabis. It mandates an initial in-person patient examination to establish a bona fide practitioner-patient relationship. While subsequent certifications and relationship maintenance can occur via telehealth, practitioners must register with the state and adhere to detailed diagnostic and counseling protocols.
The FDA's Pharmacy Compounding Advisory Committee met on July 23-24, 2026, to evaluate seven specific peptides and their related substances for potential inclusion on the Section 503A bulk drug substances list. This decision is critical for compounding pharmacies and healthcare providers offering peptide-based compounded treatments, as it dictates which substances can be legally compounded.
BPC-157 is a synthetic peptide widely marketed for purported tissue-repair and recovery uses. As of July 2026 it is not FDA-approved and not on the 503A compounding list. An FDA advisory committee voted July 23, 2026 to recommend adding it for pharmacy compounding, but that recommendation is non-binding and does not make BPC-157 legal to sell for human use.
On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six of seven peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — to the Section 503A compounding list, and rejected Emideltide (DSIP). The votes are advisory and non-binding: the peptides are not yet FDA-approved and not yet legal to compound.
After the FDA advisory panel's July 23-24, 2026 vote, peptides like BPC-157 and TB-500 are still not legal to compound or to sell for human use. The committee only recommended adding six peptides to the 503A pharmacy-compounding list; final legality requires FDA rulemaking expected no earlier than 2027.
